CHURCHILL MANAGEMENT Corp Sells 3,707 Shares of Pfizer Inc. (NYSE:PFE)

CHURCHILL MANAGEMENT Corp lessened its stake in Pfizer Inc. (NYSE:PFE – Get Rating) by 1.0% in the fourth quarter, HoldingsChannel reports. The firm owned 366,695 shares of the biopharmaceutical company’s stock after selling 3,707 shares during the period. Pfizer accounts for about 0.4% of CHURCHILL MANAGEMENT Corp’s holdings, making the stock its 24th biggest position. CHURCHILL MANAGEMENT Corp’s holdings in Pfizer were worth $18,789,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in PFE. Karp Capital Management Corp bought a new stake in shares of Pfizer in the third quarter worth about $27,000. Worth Asset Management LLC bought a new stake in shares of Pfizer in the first quarter worth about $29,000. Delos Wealth Advisors LLC increased its holdings in shares of Pfizer by 100.0% in the third quarter. Delos Wealth Advisors LLC now owns 800 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 400 shares in the last quarter. Legend Financial Advisors Inc. bought a new stake in shares of Pfizer in the third quarter worth about $42,000. Finally, Align Wealth Management LLC acquired a new position in shares of Pfizer during the fourth quarter worth about $45,000. Institutional investors own 67.62% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. SVB Leerink reduced their price objective on Pfizer from $49.00 to $48.00 and set a “market perform” rating for the company in a research report on Wednesday, February 1st. BMO Capital Markets reduced their price objective on Pfizer from $55.00 to $53.00 and set an “outperform” rating for the company in a research report on Wednesday, February 1st. Wells Fargo & Company reduced their price objective on Pfizer from $50.00 to $44.00 and set an “equal weight” rating for the company in a research report on Friday. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and set a $51.00 price objective for the company in a research report on Tuesday, February 7th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $75.00 price objective on shares of Pfizer in a research report on Wednesday, February 1st. Nine analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $50.38.

Pfizer Stock Performance

PFE opened at $40.10 on Friday. Pfizer Inc. has a 12-month low of $39.23 and a 12-month high of $56.32. The stock has a market cap of $225.33 billion, a price-to-earnings ratio of 7.32, a PEG ratio of 1.33 and a beta of 0.64. The business has a 50 day moving average of $43.26 and a 200-day moving average of $46.03. The company has a quick ratio of 1.00, a current ratio of 1.22 and a debt-to-equity ratio of 0.34.

Pfizer (NYSE:PFE – Get Rating) last released its quarterly earnings data on Tuesday, January 31st. The biopharmaceutical company reported $1.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.03 by $0.11. Pfizer had a return on equity of 42.03% and a net margin of 31.27%. The company had revenue of $24.30 billion during the quarter, compared to analysts’ expectations of $24.40 billion. During the same period last year, the firm posted $1.08 earnings per share. The business’s revenue was up 1.9% on a year-over-year basis. On average, equities research analysts expect that Pfizer Inc. will post 3.33 earnings per share for the current year.

Pfizer Company Profile

(Get Rating)

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.